CVS Health's Options Frenzy: What You Need to Know
Deep-pocketed investors have adopted a bearish approach towards CVS Health (NYSE:CVS), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled
Dividend Roundup: Procter & Gamble, Costco, CVS Health, Colgate-Palmolive, and More
Is Big Pharma Poised To Take Over Cannabis? 3 Companies Already Manage 8 In 10 Drug Prescriptions In The US
The U.S. Federal Trade Commission (FTC) recently highlighted the significant influence of pharmacy benefit managers (PBMs) on drug prices due to market consolidation. This trend raises critical
CVS Health Corporation's (NYSE:CVS) Fundamentals Look Pretty Strong: Could The Market Be Wrong About The Stock?
CVS Health (CVS) Stock Falls Amid Market Uptick: What Investors Need to Know
FTC to Sue Pharmacy Benefit Managers Over Insulin Prices
By Liz Essley Whyte and Anna Wilde Mathews The Federal Trade Commission is preparing to sue the largest three pharmacy-benefit managers over their tactics for negotiating prices for drugs including
Sector Update: Health Care Stocks Higher Late Afternoon
Health care stocks rose late Wednesday afternoon, with the NYSE Health Care Index and the Health Care Select Sector SPDR Fund (XLV) each up about 0.7%.The iShares Biotechnology ETF (IBB) added 1%.In
Express News | CVS Health Shares Down 0.6%, UnitedHealth up 1.2% in Afternoon Trading; Reuters Reports, Citing Source, That FTC to Sue UnitedHealth Group’s Optumrx, Cigna Group’s Express Scripts and CVS Health’s Caremark Over Insulin Prices
Update: Market Chatter: FTC to Sue Pharmacy Benefit Managers Over Drug Prices
(Updates with additional details throughout.)The Federal Trade Commission plans to sue the three largest pharmacy-benefit managers, including OptumRx, Express Scripts, and CVS Caremark, over their
Express News | CVS Health Down 1.3% After Report US FTC to Sue Co Over Insulin Prices
Express News | FTC to Sue UnitedHealth Group’s Optumrx, Cigna Group’s Express Scripts and CVS Health’s Caremark Over Insulin Prices- WSJ
FTC to Sue Drug Managers Over Insulin Prices -- WSJ
By Liz Essley Whyte and Anna Wilde Mathews The Federal Trade Commission is preparing to sue the largest three pharmacy-benefit managers over their tactics for negotiating prices for drugs including
10 Health Care Stocks Whale Activity In Today's Session
This whale alert can help traders discover the next big trading opportunities.Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity
Unusual Options Activity: CFLT, FSLR and Others Attract Market Bets, CFLT V/OI Ratio Reaches 655.0
EST Jul 10th Afternoon Delivery - In the last two hours of trading, 9 options with a high V/OI ratio were detected. With the market volatile, it's crucial to stay informed on the latest options
Evercore Maintains CVS Health(CVS.US) With Buy Rating, Maintains Target Price $65
Evercore analyst Elizabeth Anderson CFA maintains $CVS Health(CVS.US)$ with a buy rating, and maintains the target price at $65.According to TipRanks data, the analyst has a success rate of 38.9%
CVS Health (CVS) Receives a Buy From Evercore ISI
Three major pharmaceutical benefit management companies in the USA will attend the congressional hearing on July 23.
Executives of the three largest pharmaceutical benefit management companies (PBM) in the United States - Optum under UnitedHealth, CVS Caremark under CVS Health, and Express Scripts under the Cigna Group - will testify before the House Oversight Committee on July 23.
Update: US FTC Report Says Pharmacy Benefit Managers Contribute to Higher Drug Costs
(Updates to add comment from United Health's Optum in the seventh paragraph.)CVS Health's (CVS) Caremark, UnitedHealth Group's (UNH) Optum, and Cigna Group's (CI) Express Scripts are among the top
Leading PBMs to Face Congressional Hearing on July 23: Axios
Drug Middlemen Pay Higher Prices to Their Own Pharmacies, Says FTC
(July 9): Drug middlemen paid their own mail-order pharmacies as much as 200 times more than the price at rival pharmacies for commonly prescribed cancer drugs, allowing them to bring in at least US$1 billion (RM4.71 billion) in excess revenue and potentially raising the costs to patients, the US Federal Trade Commission (FTC) found in an interim study.